Altimmune, Inc.
ALTHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframePart of the healthcare sector, Altimmune, Inc. (ALT) is listed under Biotechnology. Valued at $412.4M, ALT is a small-cap name in its sector. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.
Market Cap
$412.4M
Beta
0.06
P/E (TTM)
—
P/E (Fwd)
-3.17
EPS (TTM)
$-0.76
EPS (Fwd)
$-0.67
ROE
-28.9%
ROA
-17.2%
Cash
$326.3M
Total Debt
$36.0M
Free CF
-$48.8M
52W Change
-46.3%
Annual Financials
Cash vs Debt
Where ALT stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ALT finished 25.67% below its 150-day moving average ($3.00) and 33.83% below its 200-day moving average ($3.37). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ALT overbought or oversold?
At the October 20, 2026 close, ALT's RSI(14) was 9.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $326.3M in cash comfortably exceeding the $36.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$48.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -28.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from -$68K (2022) to $41K (2025), reflecting a 160% increase over the period.
ALT's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, ALT has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing ALT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.